GSA Capital Partners LLP Decreases Stake in Design Therapeutics, Inc. (NASDAQ:DSGN)

GSA Capital Partners LLP cut its stake in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) by 17.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 173,744 shares of the company’s stock after selling 36,209 shares during the quarter. GSA Capital Partners LLP’s holdings in Design Therapeutics were worth $935,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in DSGN. Frazier Life Sciences Management L.P. purchased a new stake in Design Therapeutics during the 2nd quarter valued at about $4,004,000. Point72 Asset Management L.P. lifted its holdings in shares of Design Therapeutics by 66.9% during the second quarter. Point72 Asset Management L.P. now owns 990,801 shares of the company’s stock worth $3,319,000 after purchasing an additional 397,285 shares during the period. Vanguard Group Inc. boosted its position in Design Therapeutics by 29.0% in the first quarter. Vanguard Group Inc. now owns 1,285,962 shares of the company’s stock valued at $5,182,000 after buying an additional 288,803 shares during the last quarter. Almitas Capital LLC increased its holdings in Design Therapeutics by 22.1% in the 2nd quarter. Almitas Capital LLC now owns 1,253,248 shares of the company’s stock worth $4,198,000 after buying an additional 227,180 shares during the period. Finally, Acadian Asset Management LLC raised its position in Design Therapeutics by 123.3% during the 1st quarter. Acadian Asset Management LLC now owns 403,546 shares of the company’s stock worth $1,625,000 after buying an additional 222,805 shares during the last quarter. 56.64% of the stock is owned by institutional investors and hedge funds.

Design Therapeutics Stock Down 3.7 %

Shares of DSGN opened at $5.80 on Friday. The company has a market capitalization of $328.40 million, a price-to-earnings ratio of -6.82 and a beta of 1.83. Design Therapeutics, Inc. has a 52 week low of $2.13 and a 52 week high of $7.77. The stock’s 50-day moving average price is $5.51 and its 200-day moving average price is $4.66.

Analysts Set New Price Targets

Separately, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $4.00 price objective on shares of Design Therapeutics in a report on Tuesday, August 6th.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.